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with both antiplatelet drugs and oral antico‑
agulants (OACs). This is related to the aging of 
society, concomitant coronary artery disease 
(CAD), peripheral artery disease (PAD), heart 
failure, and atrial fibrillation (AF). Additionally, 
The rationale behind the experts’ opinion 
The need for an experts’ opinion arises directly 
from the rapid development of pharmacology and 
clinical cardiology, and from the fact that an in‑
creasing group of patients requires treatment 
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ABSTRACT
Oral anticoagulants (OACs) are widely used for prevention of systemic thromboembolism, including 
the reduction of the risk of stroke in patients with atrial fibrillation (AF) and prosthetic heart valves. There 
is also an increasing population of patients who require not only OACs, but also double antiplatelet therapy 
(DAPT). A typical example is a patient with AF and stable coronary artery disease or acute coronary syndrome 
(ACS), treated by percutaneous coronary intervention. In recent years, with the introduction of NOACs, triple 
or dual therapy has become safer. Regardless of these indications for the use of NOACs, rivaroxaban at a 
reduced dose has proved to efficiently reduce the risk of further thrombotic events when added to DAPT in 
patients who have suffered an ACS. However, such therapy increases the incidence of bleeding complications. 
Interesting was also the potential impact of the pleiotropic mechanism of action of non–vitamin K antagonist 
oral anticoagulants (NOACs) through protease‑activated receptors 1 and 2, present on the platelets and 
many other cells, and changing the course of arterial atherosclerosis. The COMPASS trial has shown that in 
the group treated with rivaroxaban combined with aspirin, the primary outcome (cardiovascular death, 
stroke, and myocardial infarction) occurred significantly less frequently than in the group treated only with 
aspirin. However, a significantly higher number of bleedings was observed. In the subgroup of patients with 
peripheral artery disease, a significant reduction of the incidence of amputations was shown. The outcomes 
of the COMPASS trial might be a breakthrough in the treatment of coronary and peripheral atherosclerosis.
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treatment with VKA + DAPT.1,2 Furthermore, 
the recently published COMPASS trial (Cardio‑
vascular Outcomes for People Using Anticoag‑
ulation Strategies) documented the role of ri‑
varoxaban in the prevention of cardiovascular 
events in patients with stable CAD and PAD.3
In this document, we discuss the novel indica‑
tions for NOACs based on recently published tri‑
als. Also, we highlight the differences in dosing 
regimens dependent not only on renal function 
and bleeding risk but also on the indication and 
the presence of AF. We also believe that it is in‑
creasingly important for clinicians to be familiar 
with the mechanisms of action and pharmacoki‑
netics of NOACs. These drugs do not require rou‑
tine monitoring of international normalized ra‑
tio (INR), which is an unquestionable advantage. 
However, in the event of an urgent surgery or 
a bleeding episode, monitoring the effect of NO‑
ACs is more difficult and also depends on the time 
elapsed from the drug ingestion. Given that 4 NO‑
ACs are now available, clinicians should famil‑
iarize themselves with the impact of renal func‑
tion on the metabolism of each of these drugs to 
choose the optimal treatment for their patients.
The relevance of this group of drugs is high‑
lighted by the fact that they are discussed in detail 
in the guidelines and experts’ opinion of the Eu‑
ropean Heart Rhythm Association, the guidelines 
for treatment of myocardial infarction and car‑
diac revascularization, and in the European So‑
ciety of Cardiology (ESC) clinical practice guide‑
lines on the use of antiplatelet drugs.4-7 The main 
indications for NOACs are listed in TABLE 1.
Additionally, the outcomes of the COMPASS 
trial provide a basis for using rivaroxaban (2.5 mg 
twice daily) combined with acetylsalicylic acid 
(ASA) as an effective method for the prevention 
of mortality, stroke, and myocardial infarction in 
patients with stable CAD and PAD who have si‑
nus rhythm. However, it should be remembered 
that bleeding risk increases with this treatment, 
meaning that it should be always individualized 
depending on the risk of ischemic and hemor‑
rhagic incidents. Effective prevention of ischemic 
complications is the primary objective of treat‑
ment in patients with atherosclerosis. The use 
of this lower “vascular” dose of rivaroxaban is 
the beginning of a new age of pharmacological 
prevention of atherosclerotic complications. In 
the following experts’ opinion, we will attempt to 
explain why we believe this statement to be true.
Molecular mechanisms of action and pharma-
cokinetics and pharmacodynamics of non–vi-
tamin K antagonist oral anticoagulants (NO-
ACs). Differences between oral anticoagu-
lants and NOACs In the 20th century, the only 
OAC available in Poland, and other Eastern Eu‑
ropean countries, was acenocoumarol. In 2006, 
warfarin was registered in Poland as the sec‑
ond VKA. From the viewpoint of therapeutic 
there is also a significant impact of the bleeding 
risk based on validated scores on the decision on 
the type of antithrombotic treatment.
Combination therapy with antiplatelet drugs 
and OACs is used not only because of coexisting 
CAD and AF, but also as a secondary prevention 
following acute coronary syndromes (ACSs) in 
patients who do not require long‑term antico‑
agulation for stroke prevention. The similari‑
ties between activation of the coagulation sys‑
tem and inflammatory mediators in coronary 
and peripheral atherosclerosis justify the use 
of OACs combined with antiplatelet drugs in 
patients with PAD. It has been shown that de‑
spite aggressive antiplatelet treatment, the re‑
sidual risk of thrombosis persists but can be re‑
duced with anticoagulants.
Clinical observations of patients with CAD, 
in particular after ACS, have shown that despite 
dual antiplatelet therapy (DAPT), the recurrence 
of cardiovascular events is frequent, which in‑
dicates a need for improving secondary preven‑
tion strategies. The insight into coagulation dis‑
orders, which can persist after an acute phase of 
an ischemic episode, has given rise to the idea of 
combined antiplatelet and anticoagulation ther‑
apy. Such an approach is possible because non–
vitamin K antagonist oral anticoagulants (NO‑
ACs) are less likely than vitamin K antagonists 
(VKAs) to cause clinically significant bleeding. 
This has made it possible to conduct randomized 
clinical trials to assess DAPT or single antiplate‑
let therapy combined with NOAC after ACS and 
in patients undergoing percutaneous coronary 
intervention (PCI), both with coexisting AF and 
without. Based on the outcomes of those trials, 
it can be concluded that the combined treat‑
ment (NOAC + DAPT or NOAC + single anti‑
platelet drug) after ACS reduces the incidence 
of recurrent ischemic cardiovascular events, 
although at the cost of increased risk of bleed‑
ing in long‑term follow‑up. However, there was 
a reduced incidence of bleeding observed with 
NOACs after PCI as compared with standard 
TABLE 1 Clinical application of non–vitamin K antagonist oral anticoagulants
Clinical application Dabigatran Apixaban Edoxaban Rivaroxaban
Stroke and systemic 
embolism prevention 
in patients with 
nonvalvular atrial 
fibrillation
+ + + +
Management/
prevention of deep 
vein thrombosis and 
pulmonary embolism
+ + + +
Prevention of ischemic 
events in patients 
with atherosclerosis 
of coronary and 
peripheral arteries
‑ ‑ ‑ +
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are not relevant in this group of patients.9 Fur‑
thermore, all of the above medications have 
a  different impact on coagulation parame‑
ters, depending on the current plasma levels of 
the drug. Therefore, in order to correctly inter‑
pret coagulation parameters during treatment 
with NOACs, the physician must know the time 
elapsed from the last dose of the drug, and also 
the time to peak and trough plasma levels of 
the drug. The results obtained from a blood sam‑
ple collected 3 hours after taking the drug will be 
significantly different from those obtained after 
12 or 24 hours, or even 6 hours after the drug 
has been taken. TABLE 2 provides the expected rang‑
es of the peak and trough plasma levels of spe‑
cific NOACs, and of the blood coagulation pa‑
rameters impacted by those drugs.4 Further‑
more, depending on the patient’s general condi‑
tion, sometimes it is necessary to consider also 
the changes in the half‑life of the drug, which 
depend, among other, on renal function. This is 
particularly important for dabigatran, which is 
metabolized mostly in the kidneys.
In the case of NOACs, fewer interactions 
with food have been observed as compared 
with VKAs. The food ingestion does not af‑
fect the action of dabigatran and apixaban, 
and those 2 medications can be taken with 
or without food.10,11 The absorption of dabiga‑
tran depends on the acid‑alkaline balance in 
efficiency, there is not much difference between 
the 2 medications; however, because warfarin 
was more often used in most Western European 
countries, it was tested in clinical trials on anti‑
coagulation and is listed in guidelines.
NOACs made their debut on the pharmaceu‑
tical market in the first decade of the 21st cen‑
tury. Unlike VKAs, which reduce the synthesis 
of coagulation factors from the prothrombin 
group (factors II, VII, IX, and X) and of antico‑
agulant proteins C and S, the novel drugs are 
highly selective towards the individual compo‑
nents of the coagulation cascade, namely, fac‑
tor Xa or thrombin (factor IIa), which are com‑
mon elements of the extrinsic and the intrinsic 
coagulation pathways.8 A simplified diagram of 
the mechanisms of action of VKAs and NOACs 
is provided in FIGURE 1.
NOACs do not require routine monitoring of 
coagulation parameters, and changes in the INR 
do not necessitate dose adjustments. Howev‑
er, the quantitative assessment of the action 
of these drugs and their anticoagulant activi‑
ty might be necessary in life‑threatening con‑
ditions, such as severe thrombotic or bleeding 
events, the need for urgent surgery, acute hepat‑
ic or renal failure, interaction with other drugs, 
or overdose.
Compared with VKAs, monitoring the action 
of NOACs is much more difficult. The INR assays 
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FIGURE 1 Mechanism 
of action of oral 
anticoagulants (based on 
Salem et al8)
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agents. This issue has been discussed in detail 
in the new 2018 practical guidelines of the Eu‑
ropean Hearth Rhythm Association.4
The mechanism of action of NOACs is also re‑
lated to the inhibition of protease‑activated re‑
ceptors (PARs). Inhibition of PAR1 and PAR2 im‑
pacts multiple cells other than platelets and 
hampers a number of processes leading to ath‑
erosclerosis. Importantly, rivaroxaban affects 
not only PAR1 (as do VKAs and the direct throm‑
bin inhibitor dabigatran), but also PAR2, thus re‑
ducing local inflammation, migration of leuko‑
cytes through endothelium, angiogenesis, and 
the volume of the atherosclerotic plaque in an‑
imal models, translating directly into anti‑in‑
flammatory and antiatherosclerotic action. How‑
ever, although the PAR2 inhibition hypothesis is 
based on experimental in vitro models, the anal‑
ysis of other clinical trials of PAR‑affecting drugs 
appears to confirm that medications devoid of 
impact on PA2 are less beneficial. One example 
of such a drug is vorapaxar, a PAR1 antagonist 
which reduces the risk of revascularization in pa‑
tients with PAD, while increasing bleeding risk 
due to the dominant PAR1 distribution on plate‑
lets.14 The pleiotropic effect of rivaroxaban seems 
most likely if we consider the fact that beneficial 
effects can be observed even for small, “vascu‑
lar” doses of the drug (2 × 2.5 mg), and the reduc‑
tion of the primary endpoint, namely, all‑cause 
mortality, in the COMPASS trial is characteris‑
tic for pleiotropic drugs. The mechanism of ac‑
tion of NOACs through PAR1 and PAR2 is illus‑
trated in FIGURE 2.15
the gastrointestinal tract, but drugs such as 
proton pump inhibitors and H2 receptor antag‑
onists have only a minor impact on its absorp‑
tion. Thus, dabigatran can be taken concomi‑
tantly with those agents.12,13 On the other hand, 
taking rivaroxaban with food increases its ab‑
sorption and bioavailability by around 39%, so 
it is recommended to take this drug with food. 
Detailed information on the absorption, bio‑
availability, and metabolism of specific NOACs 
is provided in TABLE 3.
Despite the fact that, compared with VKAs, 
NOACs have markedly fewer interactions, ad‑
verse reactions caused by concomitant use of 
other substances cannot be ruled out for those 
TABLE 2 Plasma levels of non–vitamin K antagonist oral anticoagulants 
(NOACs), and blood coagulation parameters in patients treated with NOACs4
Parameter Dabigatran Apixaban Edoxaban Rivaroxaban
Expected peak plasma 
level range, ng/ml
64–443 69–321 91–321 184–343
Expected trough 
plasma level 
range, ng/ml
31–225 34–230 31–230 12–137
PT ↑ (↑) ↑(↑) ↑ ↑(↑)
aPTT ↑ ↑(↑) (↑) ↑ ↑
ACT ↑(↑) ↑ ↑ ↑
dTT ↑ ↑ ↑ ↑ – – –
Abbreviations: ACT, activated clotting time; aPTT, activated partial thromboplastin time; dTT, diluted 
thrombin time; PT, prothrombin time
TABLE 3 Absorption and metabolism of non–vitamin K antagonist oral anticoagulants4
Properties Dabigatran Apixaban Edoxaban Rivaroxaban
Bioavailability, % 3–7 50 62 66 when taken without food; 
80–100 with food
Prodrug Yes No No No
Nonrenal/renal clearance in 
percentages of the dose (with 
nonimpaired renal function), %
20/80 73/27 50/50 65/35
Binding to plasma proteins, % 35 87 55 95
Hepatic metabolism: using CYP3A4 No Yes (elimination, moderate 
participation of 
CYP3A4 ~25%
Minimal (elimination 
<4%)
Yes (hepatic elimination 
~18%)
Absorption depending on food intake No impact No impact Absorption improved 
by 6%–22%
Absorption improved by 39%
Absorption depending on the use of 
H2 receptor antagonists and proton 
pump inhibitors, %
–12 to –30 No impact No impact No impact
Asian patient effect, % +25 No impact No impact No impact
Half‑life, h 12–17 12 10–14 5–9 in younger patients; 
11–13 in older patients
Other Dyspepsia 
(5%–10%)
– – 15 mg/20 mg doses – 
obligatory taking with food
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frequent use of NOACs than VKAs, and use dual 
therapy, that is, OACs combined with only 1 an‑
tiplatelet agent, to reduce the risk of hemorrhag‑
ic complications. At the same time, such an ap‑
proach seems to be safe and does not increase 
the risk of recurrent ischemia and mortality.4,6,7
The first randomized trial to demonstrate 
the benefits of a single antiplatelet drug com‑
bined with warfarin was WOEST (What is 
the Optimal antiplatElet and anticoagulant ther‑
apy in patients with oral anticoagulation and 
coronary StenTing).1 The trial assessed treat‑
ment with clopidogrel and warfarin as compared 
with standard triple therapy with the addition 
of ASA. The risk of bleeding events was reduced 
in the group treated only with clopidogrel and 
VKA compared with the standard triple thera‑
py, mainly due to lower rates of minor bleeding 
(major and minor bleedings, 14.0% vs 31.3%, re‑
spectively, P <0.0001; major bleedings, 3.2% vs 
5.6%, P = 0.16). The rate of myocardial infarc‑
tions (3.25% vs 4.6%), stroke (1.1% vs 2.8%), re‑
peated target vessel revascularization (7.2% vs 
6.7%), and stent thrombosis (1.4% vs 3.2%) did 
not differ significantly between the groups. To‑
tal mortality after 1 year was significantly lower 
in the dual therapy group (2.6% vs 0% to 6.4%, 
P = 0.027).1 Nevertheless, the study lacked sta‑
tistical power to allow a reliable assessment of 
the impact of the applied therapies on long‑term 
clinical outcomes.
Further studies compared strategies of stan‑
dard triple therapy (VKA + DAPT), NOAC and 
a single antiplatelet agent versus NOACs and 
Outcomes of randomized trials comparing 
vitamin K antagonists and non–vitamin K 
antagonist oral anticoagulants in patients 
with atrial fibrillation undergoing percuta-
neous coronary intervention Optimal com‑
bined antiplatelet and anticoagulant therapy 
and the length of the combined treatment in pa‑
tients with AF undergoing PCI is still extensive‑
ly studied. Initiating 1 or 2 antiplatelet agents 
after PCI in patients who require anticoagulant 
treatment increases the bleeding risk. Dual anti‑
platelet treatment can be shortened or extended, 
depending on the clinical and angiographic as‑
sessment of the patient, rather than the type of 
the stent used (drug‑eluting stent or bare metal 
stent). Drug‑eluting stents are associated with 
a lower risk of stent thrombosis in the long‑term 
than bare metal stents. Furthermore, recent 
studies suggest that short DAPT (1 month after 
the procedure in patients with stable angina, or 
6 months after ACS) is safe for elderly patients 
and those with a high risk of bleeding compli‑
cations.16 -19 The currently applicable treatment 
strategies for patients after elective PCI, pub‑
lished in the guidelines are constantly evolving 
according to the outcomes of the latest research. 
The trend of those changes especially in patients 
with high bleeding risk leans towards a more 
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overt nonmajor bleeding, as well as of major 
bleeding events assessed separately, was signifi‑
cantly reduced in groups receiving dual therapy 
with 110 mg and 150 mg of dabigatran, as com‑
pared with standard triple therapy with VKA 
and DAPT. Although the lack of statistical pow‑
er of the trial did not allow for a reliable assess‑
ment of individual components of the endpoint 
separately, it showed that NOAC and single an‑
tiplatelet drug are noninferior to standard tri‑
ple therapy regarding the composite endpoint 
(death, stroke, thromboembolic events, or un‑
planned revascularization) (P = 0.005). In pa‑
tients with AF who were undergoing PCI, both 
doses of dabigatran used in the RE‑DUAL PCI 
trial, combined with a P2Y12 inhibitor, signifi‑
cantly reduced bleeding complications as com‑
pared to triple therapy with warfarin, a P2Y12 in‑
hibitor, and ASA.2 There was also equivalence in 
observed prevention of thromboembolic events. 
Additionally, a meta‑analysis of the WOEST, PI‑
ONEER AF‑PCI, and RE‑DUAL PCI studies sug‑
gested that the probability of an increased risk 
of thromboembolic events during dual therapy 
is low compared to triple therapy.21
Two ongoing studies with NOACs (ENTRUST‑ 
‑AF PCI [Edoxaban Treatment Versus Vitamin 
K Antagonist in Patients With Atrial Fibrilla‑
tion Undergoing Percutaneous Coronary Inter‑
vention] and AUGUSTUS [A Study of Apixaban 
in Patients With Atrial Fibrillation, Not Caused 
by a Heart Valve Problem, Who Are at Risk for 
Thrombosis (Blood Clots) Due to Having Had 
a Recent Coronary Event, Such as a Heart Attack 
or a Procedure to Open the Vessels of the Heart]) 
will undoubtedly expand our knowledge and 
should provide answers to the questions of how 
long triple therapy should be used after PCI in 
patients with AF, and whether it should be used 
at all.22,23 In particular, the AUGUSTUS trial with 
apixaban should provide insight into whether 
administering dual therapy with apixaban and 
clopidogrel, and dual therapy with warfarin and 
clopidogrel, has comparable or higher efficacy 
than respective triple therapies, and if so, then 
which of the 4 studied treatment strategies is op‑
timal in terms of benefits and protection against 
ischemic events and the risk of bleeding compli‑
cations. The difficulties with providing the clear 
guidelines also arise from the fact that the stud‑
ies with both rivaroxaban and dabigatran did 
not have sufficient statistical power to confirm 
the equivalence of reduced doses of those agents 
in the prevention of stent thrombosis and other 
ischemic events.
Additionally, data supporting the combina‑
tion of NOACs with ticagrelor or prasugrel are 
limited. NOACs are currently not recommend‑
ed for triple therapy regimens with these more 
potent P2Y12 inhibitors by the latest ESC guide‑
lines. Nevertheless, the situation may be differ‑
ent in dual therapy regimens.7 In a subgroup of 
DAPT. The PIONEER AF‑PCI trial (Open‑Label, 
Randomized, Controlled, Multicenter Study Ex‑
ploring Two Treatment Strategies of Rivaroxaban 
and a Dose‑Adjusted Oral Vitamin K Antagonist 
Treatment Strategy in Subjects with Atrial Fibril‑
lation who Undergo Percutaneous Coronary In‑
tervention) assessed the safety of 3 treatment 
strategies after PCI with stent implantation in 
2124 patients with paroxysmal, persistent, or 
permanent AF.20 The applied treatment regi‑
mens were as follows: 1) rivaroxaban in small 
doses, ie, 15 mg once daily (10 mg if creatinine 
clearance was 30 to 50 ml/min) plus a P2Y12 in‑
hibitor for 12 months; 2) rivaroxaban in very 
small doses (2.5 mg twice daily) plus DAPT for 
1, 6, or 12 months. After the completion of 1‑ or 
6‑month DAPT, the patient received 15 mg once 
daily of rivaroxaban (10 mg if creatinine clear‑
ance was 30 to 50 ml/min) plus a small dose of 
ASA (75 to 100 mg/d) for the remaining part of 
the 12‑month treatment; 3) standard triple ther‑
apy with VKA (warfarin) once daily (target INR, 
2.0–3.0) plus DAPT for 1, 6, or 12 months. The pa‑
tients treated with 1‑ or 6‑month regimens were 
subsequently treated with warfarin and ASA in 
doses as specified above for the remaining part 
of the 12‑month treatment.
The PIONEER AF‑PCI trial showed that both 
dosing regimens of rivaroxaban reduced the risk 
of clinically relevant bleeding complications af‑
ter 1 year of treatment, as compared with stan‑
dard triple therapy with VKA and variable dura‑
tion of DAPT (16.8% in group 1, 18.0% in group 
2, and 26.7% in group; hazard ratio [HR] 1 vs 2, 
0.59; 95% CI, 0.47–0.76; HR 2 vs 3, 0.63; 95% CI, 
0.50–0.80). In both groups treated with rivar‑
oxaban, there was also a much lower incidence 
of bleeding episodes requiring medical atten‑
tion than in the standard therapy group (HR 
1 vs 3, 0.61; 95% CI, 0.47–0.80; HR 2 vs 3, 0.67; 
95% CI, 0.52–0.86). The rate of cardiovascular 
death, myocardial infarction, and stroke was 
comparable across the 3 groups. Nevertheless, 
the statistical power of the trial for the assess‑
ment of these secondary endpoints was insuf‑
ficient to draw definite conclusions. The rate of 
stent thrombosis was low and similar across all 
groups. It should also be pointed out that riva‑
roxaban 2.5 mg twice daily had not been previ‑
ously studied in the context of stroke preven‑
tion in patients with AF.20
The RE‑DUAL PCI trial (Evaluation of Dual 
Therapy With Dabigatran vs. Triple Therapy 
With Warfarin in Patients With AF That Un‑
dergo a PCI With Stenting) assessed the safety 
of 2 doses of dabigatran (110 mg or 150 mg twice 
daily) combined with clopidogrel or ticagrelor 
(dual therapy without aspirin), as compared with 
standard triple therapy (VKA, ASA, and clopi‑
dogrel or ticagrelor) in 2725 patients with AF 
who were undergoing PCI.2 The rate of the com‑
posite endpoint major bleeding and clinically 
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496 TABLE 4 Summary of the outcomes of randomized trials on the use of oral anticoagulants and non–vitamin K antagonist oral anticoagulants after percutaneous coronary intervention in patients with 
atrial fibrillation (continued on the next page)
Trial / drug Purpose No. of 
patients
Selected inclusion criteria Selected exclusion criteria Endpoints Conclusions
WOEST1
VKA
Assessment of treatment with 
clopidogrel alone compared with 
ASA combined with clopidogrel in 
patients treated with oral 
anticoagulation after PCI
573 • Age 18–80 y 
• Long‑term indication for 
OACs (at least 1 year after 
the end of study)
• Significant coronary artery 
disease (at least 75% 
occlusion confirmed by 
angiography, or FFR <0.80), 
with an indication for PCI
• Intracranial bleeding 
episodes
• Cardiogenic shock
• Peptic ulcer within 
the previous 6 months
• Thrombocytopenia (PLT 
levels <50 × 109/l)
• Major bleeding within 
the previous 12 months 
(according to TIMI score)
Primary endpoint:
• Occurrence of any bleeding 
episode during 1‑year follow‑up
Additional endpoints:
• Death
• Myocardial infarction
• Stroke
• Repeated revascularization of 
artery after pci
• Stent thrombosis
In patients taking OACs and 
undergoing PCI, the use of 
clopidogrel without aspirin 
significantly reduced hemorrhagic 
complications and did not increase 
the incidence of thrombotic events.
PIONEER 
AF‑PCI20
Rivaroxaban
Assessment of 3 management 
strategies in patients with 
nonvalvular AF who were 
undergoing PCI: 
1. Rivaroxaban 15 mg or 10 mg 
once daily + P2Y12 inhibitor for 
12 months 
2. Rivaroxaban 2.5 mg twice daily 
+ DAPT for 1, 6, or 12 months, 
followed by rivaroxaban 15 mg or 
10 mg once daily + ASA for up to 
12 months 
3. Standard triple therapy with 
warfarin once daily (INR 2.0–3.0) 
+ DAPT for 1, 6, or 12 months, 
followed by warfarin + ASA for up 
to 12 months
2124 • Paroxysmal, persistent, or 
permanent nonvalvular AF
• Current PCI with stent 
implantation
• History of stroke or TIA
• Clinically relevant 
gastrointestinal bleeding 
within the previous 
12 months
• Creatinine clearance below 
30 ml/min
• Anemia of unknown etiology 
with hemoglobin levels 
below 10 g/dl
• Other conditions known to 
increase bleeding risk
Primary safety endpoint:
• Occurrence of clinically relevant 
bleeding during 1‑year 
follow‑up
Secondary endpoints:
• Major bleeding, minor bleeding, 
bleeding episodes requiring 
medical consultation, analyzed 
separately
• Cardiovascular death, heart 
attack or stroke, analyzed 
jointly
In patients with AF who were 
undergoing PCI with stent 
implantation, treatment with 
rivaroxaban in small dose 
combined with P2Y12 inhibitor for 
12 months, and rivaroxaban in very 
small dose combined with DAPT for 
1, 6, or 12 months was associated 
with a lower percentage of 
clinically overt bleeding episodes 
than standard treatment with OACs 
combined with DAPT. The efficacy 
of treatment was similar across 
the 3 groups; nevertheless, due to 
the broad CIs, the trial was 
inconclusive in this aspect.
RE‑DUAL PCI24
Dabigatran
Assessment of safety and efficacy of 
dual regimen (P2Y12‑inhibitor 
without ASA + dabigatran) 
compared with triple regimen 
(2 antiplatelet agents + warfarin) in 
patients with nonvalvular AF who 
were undergoing PCI: 
1. Dabigatran 110 mg twice daily 
+ P2Y12 inhibitor 
2. Dabigatran 150 mg twice daily 
+ P2Y12 inhibitor 
3. Warfarin + P2Y12 inhibitor + ASA 
<100 mg for 3 months (BMS) / 
6 months (DES)
2725 • Patients with nonvalvular AF 
who were treated with VKAs 
or not before PCI, but had 
indications for long‑term 
anticoagulant therapy
• ACS treated with PCI with 
stent implantation, or stable 
coronary artery disease 
with ≥1 lesion effectively 
treated by PCI with stent 
implantation
• Cardiogenic shock or 
thrombolytic therapy of ACS
• Stroke within the previous 
month
• Major surgery within 
the previous month
• Major bleeding within 
the previous month
• Anemia
• Kidney failure (eCrCl 
<30 ml/min), active liver 
disease
Primary endpoint: occurrence of 
a major or clinically relevant 
bleeding during 1‑year 
follow‑up
Secondary endpoint: 
thromboembolic complications 
(heart attack, stroke or other 
embolism), death, or unplanned 
revascularization, assessed 
jointly
Among patients with AF who were 
undergoing PCI, the bleeding risk 
was lower in dual regimen with 
dabigatran and P2Y12 inhibitor than 
in triple regimen with warfarin, 
P2Y12 inhibitor, and aspirin. 
The dual therapy was noninferior 
to triple therapy in terms of 
thromboembolic events risk.
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TABLE 4 Summary of the outcomes of randomized trials on the use of oral anticoagulants and non–vitamin K antagonist oral anticoagulants after percutaneous coronary intervention in patients with 
atrial fibrillation (continued from the previous page)
Trial / drug Purpose No. of 
patients
Selected inclusion criteria Selected exclusion criteria Endpoints Conclusions
ENTRUST‑AF 
PCI22
Edoxaban
Assessment whether anticoagulation 
strategy based on edoxaban 
reduced the risk of hemorrhagic 
complications of PCI compared 
with OACs combined with standard 
dual antiplatelet regimen in 
patients with AF who required 
continuous OAC. Additionally, 
the relative risk of ischemic events 
was compared between the study 
groups. 
1. Edoxaban 60 mg (or 30 mg) once 
daily + P2Y12 inhibitor (clopidogrel) 
2. VKA + P2Y12 inhibitor 
(clopidogrel) + ASA 100 mg for 
30 days
1500 • Nonvalvular AF with 
an indication for chronic 
antithrombotic therapy 
after a successful PCI with 
stent implantation
• Angiographically and 
clinically successful PCI
• High risk of major bleeding 
or a history of major 
hemorrhagic complications
• Ischemic stroke within 
the previous 2 weeks
• Uncontrolled hypertension
• Anemia (Hb <8 mg/dl)
• Kidney failure (CrCl 
<15 ml/min)
Primary safety endpoint: 
incidence of major and clinically 
overt nonmajor bleeding
Primary efficacy endpoint: 
cardiovascular death, stroke, 
thrombotic episodes, 
myocardial infarction, and some 
stent thrombosis, assessed 
jointly
The outcomes have not been 
published. The trial is ongoing, 
with planned end in March 2019.
AUGUSTUS23
Apixaban
Comparison of apixaban and 
warfarin, and the assessment of 
the risks and benefits of ASA in 
patients with AF who were treated 
with PCI for ACS 
1. Apixaban 5 mg twice daily 
(2 × 2.5 mg) + P2Y12 inhibitor + ASA 
2. Apixaban 5 mg twice daily 
(2 × 2.5 mg) + P2Y12 inhibitor 
3. Warfarin + P2Y12 inhibitor + ASA 
4. Warfarin + P2Y12 inhibitor*P2Y12 
inhibitor for 6 months, ASA from 
the date of ACS to PCI/
randomization to PCI
4600 • Paroxysmal, persistent, or 
permanent AF requiring 
antithrombotic therapy
• ACS (heart attack, unstable 
angina) treated with PCI 
within the previous 14 days
• Indications for chronic 
anticoagulation other than 
AF
• Kidney failure (CrCl 
<30 ml/min)
• Intracranial bleeding
• History of or planned CABG 
due to the presence of ACS
• Coagulopathy, active 
bleeding
Primary endpoint:
• Major or clinically overt 
non‑major bleeding within 
the previous 6 months
Main secondary endpoint:
• All‑cause death or 
hospitalization
Other secondary endpoints:
• DeathHeart attack
• StrokeStent thrombosis
• Urgent revascularization
• Hospitalization
The outcomes have not been 
published. The trial is ongoing, 
with planned end in December 
2018.
Abbreviations: ACS, acute coronary syndrome; AF, atrial fibrillation; ASA, acetylsalicylic acid; BMS, bare metal stent; CABG, coronary artery bypass grafting; CrCl, creatinine clearance; DAPT, dual antiplatelet therapy; DES, drug‑eluting stent; eCrCl, estimated 
creatine clearance; FFR, fractional flow reserve; Hb, hemoglobin; OAC, oral anticoagulant; PCI, percutaneous coronary intervention; TIA, transient ischemic attack; PLT, platelets; VKA, vitamin K antagonist
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ventricular thrombus, venous thromboembo‑
lism, etc). To reduce the bleeding risk, it is also 
recommended to shorten the triple therapy af‑
ter drug‑eluting stent implantation to 6 months, 
and in the case of a high risk of bleeding com‑
plications, to 1 month, or to use double therapy 
only. After early termination of triple therapy, 
it is recommended to continue treatment with 
dual therapy for up to 12 months after an ACS, 
with an anticoagulant (VKA or NOAC) combined 
with clopidogrel or ASA. After 12 months, it is 
recommended to switch the patient to mono‑
therapy (VKA or NOAC).7
The introduction of NOACs into clinical prac‑
tice triggered a series of studies assessing their 
safety and efficacy in the prevention of recurrent 
ischemic events in patients after ACS.
The APPRAISE II trial (Apixaban for Pre‑
vention of Acute Ischemic Events 2) assessed 
the outcome of treatment with apixaban, 5 mg 
twice daily, in patients after ACS who were re‑
ceiving standard antiplatelet therapy. A total 
of 7392 patients were enrolled, but the trial 
was terminated early due to the lack of effect 
of the study treatment on the incidence of car‑
diac mortality, myocardial infarction, and isch‑
emic stroke, with a significantly increased risk 
of hemorrhagic complications, including intra‑
cranial hemorrhages and severe fatal bleeding 
episodes.27
The RE‑DEEM trial (Dose Finding Study for 
Dabigatran Etexilate in Patients With Acute Cor‑
onary Syndrome) assessed the impact of 4 differ‑
ent doses of dabigatran (50 mg, 75 mg, 110 mg, 
and 150 mg twice daily), as compared with place‑
bo, on the risk of hemorrhagic complications and 
coagulation activity in 1861 patients after myo‑
cardial infarction (ST‑segment and non–ST‑seg‑
ment elevation myocardial infarction) who were 
receiving standard antiplatelet therapy.28 Dur‑
ing 6‑month follow‑up in the dabigatran group, 
a dose‑dependent 2‑ to 4‑fold increase of the risk 
of bleeding complications was observed, as well 
as a reduction of the procoagulation activity of 
plasma, with an average reduction of D‑dimer 
levels by 45% at 4 weeks of treatment. Howev‑
er, the trial did not have sufficient statistical 
power to assess the impact of different doses of 
dabigatran on the incidence of ischemic compli‑
cations (death, myocardial infarction, ischemic 
stroke) and to evaluate in detail the risk to ben‑
efit ratio for the study treatment.28
Then the ATLAS ACS 2–TIMI 51 trial (An‑
ti‑Xa Therapy to Lower Cardiovascular Events 
in Addition to Standard Therapy in Subjects 
with Acute Coronary Syndrome‑Thrombolysis 
In Myocardial Infarction‑51) assessed the im‑
pact of treatment with rivaroxaban 2.5 mg twice 
daily and 5 mg twice daily versus placebo on 
the risk of ischemic and bleeding complications 
in 15 526 stable patients after ACS who were 
treated with DAPT.29 Both doses of rivaroxaban 
RE‑DUAL PCI, the use of ticagrelor combined 
with dabigatran proved that both treatment reg‑
imens are safe and efficient.24 The outcomes of 
randomized trials on the use of OACs and NO‑
ACs after PCI in patients with AF are summa‑
rized in TABLE 4.
In summary, it should be noted that at the mo‑
ment, there is no definite evidence supporting 
the routine use of dual therapy regimens (NOAC 
+ P2Y12 inhibitor) in patients with AF who are 
undergoing PCI. In patients at very high risk of 
recurrent ischemia, first‑line treatment should 
be based on 1‑ to 6‑month triple therapy regi‑
mens, as recommended by the current guide‑
lines. If the bleeding risk dominates, as an al‑
ternative to the current regimens, dual therapy 
initiated immediately after PCI should be con‑
sidered for patients with nonvalvular AF who 
require chronic anticoagulation treatment: 1) 
with rivaroxaban: 15 mg once daily combined 
with clopidogrel (10 mg with creatinine clear‑
ance of 30 to 49 ml/min); 2) with dabigatran: 
150 mg twice daily or 110 mg twice daily com‑
bined with clopidogrel or ticagrelor.
Randomized trials with non–vitamin K antag-
onist oral anticoagulants (NOACs) in acute 
coronary syndromes and their clinical impli-
cations. The role of NOACs in acute coronary 
syndrome treatment: current guidelines of 
the European Society of Cardiology The es‑
sential component of the treatment after ACS, 
regardless of the adopted strategy (pharmacolog‑
ical treatment, PCI, and/or CABG), is 12‑month 
DAPT, with the combination of ASA and more 
potent P2Y12 inhibitors (ticagrelor, prasugrel) 
as the preferred regimen. Combining ASA with 
clopidogrel is recommended only for patients 
taking chronic OACs (VKAs, NOACs), with con‑
traindications to new P2Y12 inhibitors, when 
such drugs are not available, or the patient re‑
fuses the regimen due to economic reasons.
Despite implementation of the current guide‑
line recommendations, including myocardial re‑
vascularization, DAPT, and secondary preven‑
tion including aggressive reduction of low‑densi‑
ty lipoprotein cholesterol, patients after ACS are 
still exposed to high risk of recurrent cardiovas‑
cular events. This might be partially related to 
prolonged increased thrombin production, which 
is observed in patients after ACS.25 There is evi‑
dence that OACs can efficiently reduce the rate of 
ischemic events after ACS, and that the combina‑
tion of OACs and antiplatelet agents is more ef‑
ficient than using each of the class of drugs sep‑
arately. However, combined therapy with war‑
farin or acenocoumarol is related to increased 
risk of bleeding complications.26 Therefore, us‑
ing OACs combined with antiplatelet drugs is 
recommended only in patients after ACS who 
have other indications for chronic anticoagu‑
lation (AF, mechanical valve prosthesis, left 
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is, several years before the COMPASS trial.33 
The guidelines for antiplatelet therapy in stable 
CAD are similar to those for PAD, recommend‑
ing a single antiplatelet agent: ASA (IA) or clop‑
idogrel (IB). Dual antiplatelet therapy is applied 
only to patients after PCI, and OACs are admin‑
istered only if there are additional indications.33
The COMPASS trial outcomes, published in 
2017, might change the way of management 
of atherosclerosis, both in stable CAD and in 
PAD.3 The objective of the trial was to assess 
the safety and efficacy of rivaroxaban in mono‑
therapy, rivaroxaban in the vascular dose with 
aspirin, and monotherapy with aspirin in reduc‑
ing the risk of myocardial infarction, stroke, and 
cardiovascular death in CAD or PAD. It was a ran‑
domized, controlled, double‑blinded trial con‑
ducted until the specified number of cardiovas‑
cular events had occurred. A total of 27 395 pa‑
tients with stable atherosclerosis (CAD and/or 
PAD) were enrolled in the trial and randomized 
into 3 groups: 1) rivaroxaban, 2.5 mg twice dai‑
ly, and ASA, 100 mg; 2) rivaroxaban, 5 mg twice 
daily; and 3) ASA, 100 mg once daily.
Combined treatment is always associated 
with an increased risk of bleeding complications. 
Therefore, the dose of rivaroxaban for the study 
arm receiving combined treatment with ASA was 
adjusted according to the outcomes of the ear‑
lier ATLAS ACS 2‑TIMI 51 trial, as described in 
the previous section.29
The COMPASS inclusion criteria provided de‑
tailed definitions of PAD and CAD. The PAD def‑
inition was as follows (one of the following cri‑
teria met):
1 History of aortofemoral bypass
2 History of limb bypass surgery
3 History of percutaneous angioplasty of ili‑
ac arteries
4 History of percutaneous angioplasty of sub‑
inguinal arteries
5 History of limb or foot amputation due to ar‑
terial disease
6 History of intermittent claudication, with 
at least one of the following criteria, met:
a Ankle‑brachial index <0.90
b Significant (≥50%) peripheral artery oc‑
clusion, as confirmed by angiography or Dop‑
pler ultrasound examination
7 History of revascularization of carotid arteries
8 Asymptomatic stenosis of carotid artery 
(≥50%), as confirmed by Doppler ultrasound 
examination or angiography.
CAD was defined as follows (one of the fol‑
lowing criteria):
1 Myocardial infarction over the past 20 years;
2 Multivessel CAD with current or a history of 
stable or unstable angina symptoms
3 Multivessel PCI
4 Multivessel CABG.
The inclusion criteria of the COMPASS tri‑
al were PAD or CAD. The CAD criterion was 
reduced the incidence of the primary efficacy 
endpoint (cardiac death, myocardial infarction, 
and stroke), but increased the risk of bleeding 
not related to coronary artery bypass grafting 
and of intracranial bleeding, with no differenc‑
es in the incidence of fatal bleeding. The impact 
of treatment with rivaroxaban was dose depen‑
dent. The dosing regimen of 2.5 mg twice dai‑
ly significantly reduced the incidence of cardi‑
ac death (2.7% vs 4.5%, P = 0.002), as compared 
with placebo. This effect was not observed for 
the regimen of 5 mg twice daily.29
Considering the outcomes of the above stud‑
ies, the ESC guidelines for the management of 
ACSs without persistent ST‑segment elevation in 
2015, the management of acute myocardial infarc‑
tion with ST‑segment elevation in 2017, and for 
myocardial revascularization in 20 185,6,30 recom‑
mended considering of adding rivaroxaban, 2.5 mg 
twice daily, to DAPT (grade of recommendation, 
IIb; level of evidence, B) only in patients: 1) with‑
out a history of stroke or transient ischemic at‑
tack; 2) treated with clopidogrel; and 3) in whom 
an increased risk of ischemic complications is iden‑
tified, with a low risk of bleeding complications.
Clinical implications of randomized trials 
with non–vitamin K antagonist oral anti-
coagulants in chronic stable coronary ar-
tery disease and peripheral artery disease 
In the ESC guidelines on PAD, antiplatelet mono‑
therapy with ASA or clopidogrel is recommend‑
ed for all symptomatic patients (IA). For asymp‑
tomatic patients with atherosclerosis of the low‑
er extremities, antiplatelet therapy is not indi‑
cated (IIIA), while in asymptomatic patients 
with carotid stenosis exceeding 50%, antiplate‑
let treatment with a low ASA dose should be 
considered (IIaC).31 Similarly, patients after pe‑
ripheral artery interventions who underwent 
1‑month DAPT have indications for treatment 
with ASA or clopidogrel. Chronic OAC treatment 
is applied only in the event of concomitant in‑
dications for such therapy: in the case of AF or 
prosthetic heart valve implantation. Oral an‑
ticoagulants can be combined with antiplate‑
let agents in patients with a recent history of 
revascularization.
The purpose of antiplatelet therapy is to pre‑
vent ischemia of extremities, but also to pre‑
vent cardiovascular events, which are a com‑
mon cause of death in this population.32 Howev‑
er, the authors of the guidelines did not refer to 
the outcomes of the COMPASS trial, as the re‑
sults had not been published at the time. But, be‑
ing aware of the early termination of the study 
due to the confirmed benefits of low‑dose treat‑
ment with rivaroxaban + ASA, the authors of 
the guidelines took into consideration the need 
for further updating the guidelines.
The European guidelines for the manage‑
ment of stable CAD were published in 2013, that 
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that AF patients as well as patients within 1 year 
after ACS or stent implantation were excluded 
from the trial.
Other exclusion criteria in the COMPASS tri‑
al included a stroke within the previous month 
or any hemorrhagic or lacunar stroke, advanced 
heart failure: New York Heart Association func‑
tional class III or IV, significant left ventricular 
dysfunction (ejection fraction <30%), advanced 
kidney failure (estimated glomerular filtration 
rate <15 ml/min), and use of antiplatelet agents 
other than ASA.
applicable to patients aged 65 or older; for young‑
er patients, concomitant atherosclerosis in 2 or 
more vascular beds was required, or 2 or more 
additional risk factors, such as active smoking, 
diabetes, kidney failure (estimated glomeru‑
lar filtration rate <60 ml/min), heart failure, 
and nonlacunar ischemic stroke 1 month be‑
fore or earlier.
Due to those inclusion criteria, the patients 
who were enrolled in the trial had very advanced 
atherosclerosis. It should be noted that patients 
requiring OACs or DAPT were excluded. It means 
ACS
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Rivaroxaban + ASA
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ASA + prasugrel
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ASA + P2Y
12
 + rivaroxaban 
CHARISMA
ASA + clopidogrel
ATT Collaboration
ASA
CURE
ASA + clopidogrel
PLATO
ASA + ticagrelor
PEGASUS
ASA + ticagrelor
CAPRIE
Clopidogrel
ATT Collaboration
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Patient with stable CAD
Patient with stable CAD
> 12 months after ACS
a
FIGURE 3 Key illustration of the experts’ opinion on the use of non–vitamin K antagonist oral anticoagulants in patients with atherosclerosis of coronary 
and peripheral arteries in the context of other trials on antiplatelet and anticoagulation therapies.  Description: The application of optimal models of 
antiplatelet / anticoagulant therapy in patients with coronary artery disease (CAD) was the objective of multiple randomized clinical trials. The treatment 
can be divided into 3 phases: before an acute coronary syndrome (ACS) in patients with stable CAD, immediately after ACS (adopting the most common 
model of a 1‑year antiplatelet therapy after ACS), and follow‑up treatment, ie, more than 1 year after ACS. Given that long‑term management after ACS 
would not differ considerably from patient management before an ACS, the proposed figure could take the form of a circular model, where a patient who 
experienced an ACS many years earlier receives the same treatment as a patient under a coronary incident prevention strategy.  In the figure, the “green 
smiley faces” indicate the outcomes of clinical trials that currently provide the strongest evidence, in an evidence‑based medicine setting, for 
the preference of that model of treatment. The “red faces” indicate the trials in which the proposed model did not prove to be significantly better than 
the compared alternative (eg, CHARISMA trial). It should be noted that not all of the trials were randomized, prospective clinical programs (eg, ATT 
Collaboration); consequently, the use of acetylsalicylic acid (ASA) in monotherapy arises from an experts’ consensus based on extensive meta‑analysis of 
the trials, which are not marked with “faces”; some of the trials are marked as “neutral faces”: these trials provide evidence for the proposed therapy, eg, 
ASA + clopidogrel after ACS, or clopidogrel instead of ASA after ACS), but the outcomes of more recent trials have degraded them to less preferred 
management strategies than, eg, ASA + ticagrelor or ASA + prasugrel .
a An alternative only for patients without a history of stroke or transient ischemic attack, who are treated with aspirin and clopidogrel; class IIbB 
recommendation according to the European Society of Cardiology guidelines6
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For PAD, the number of deaths was 129 out of 
2492 patients (5%) in the rivaroxaban + ASA 
group vs 142  out of 2504  patients (6%) in 
the ASA group. Additionally, a significant re‑
duction in the incidence of major adverse limb 
events was shown, including amputations, which 
occurred in 32 patients (1%) treated with riva‑
roxaban + ASA vs 60 (2%) in the group treated 
with ASA alone (HR, 0.54; P = 0.0037).
It should be added that COMPASS was 
the first and thus far the only randomized tri‑
al assessing the action of NOACs in patients 
with chronic symptomatic atherosclerosis. Two 
earlier trials assessed the efficacy of warfarin 
in similar patient groups. The WARIS II trial 
(Warfarin‑Aspirin Reinfarction Study II) as‑
sessed the action of warfarin, warfarin com‑
bined with ASA, and monotherapy with ASA in 
the treatment of 3630 patients who had experi‑
enced a myocardial infarction.26 During 4 years 
of follow‑up, a significant reduction in the inci‑
dence of the composite endpoint (death, myocar‑
dial infarction, or ischemic stroke) was shown 
compared with monotherapy with ASA, both in 
patients receiving monotherapy with warfarin 
and in the combined therapy group. However, 
the use of warfarin increased the risk of major 
bleeding complications (P <0.001). In the WAVE 
trial (Warfarin Antiplatelet Vascular Evalua‑
tion Trial I), 2161 patients with PAD were ran‑
domized to groups treated with OACs combined 
with an antiplatelet agent, or monotherapy with 
an antiplatelet agent.36 During 3 years of fol‑
low‑up, in the combined therapy group, no sig‑
nificant reduction in the incidence of the com‑
posite endpoint (cardiovascular death, myocar‑
dial infarction, or stroke) or peripheral athero‑
sclerosis was shown, while an increase of the risk 
of life‑threatening bleeding was observed (rel‑
ative risk, 3.41; 95% CI, 1.84–6.35; P <0.001).36
In January 2018, enrollment into the VOYAG‑
ER PAD trial (Efficacy and Safety of Rivaroxaban 
in Reducing the Risk of Major Thrombotic Vas‑
cular Events in Subjects With Symptomatic Pe‑
ripheral Artery Disease Undergoing Peripheral 
Revascularization Procedures of the Lower Ex‑
tremities) was completed; 6500 patients with 
PAD referred for surgical or interventional treat‑
ment, who were receiving ASA, 100 mg/d, were 
randomized to receive rivaroxaban, 2 × 2.5 mg, 
or placebo. In this study, it is acceptable to simul‑
taneously administer, for a short time follow‑
ing the intervention, P2Y12 inhibitors. The study 
will end after reaching the specified number of 
1015 events included in the composite efficacy 
endpoint of cardiovascular death, myocardial in‑
farction, ischemic stroke, acute limb ischemia, or 
amputation. VOYAGER PAD is an international, 
multicenter, double‑blinded randomized trial.37
In conclusion, the outcomes of the COMPASS 
trial might be a breakthrough in the manage‑
ment of atherosclerosis. Combined treatment 
The trial was prematurely stopped due to con‑
firmation of the efficacy of rivaroxaban, 2.5 mg 
twice daily, combined with ASA. The group re‑
ceiving rivaroxaban, 5 mg twice daily, did not 
differ from ASA in terms of the occurrence of 
the composite endpoint, but the number of 
major bleeding episodes was higher in that 
group. The average follow‑up was 23 months. 
In the group receiving rivaroxaban with ASA, 
the primary endpoint of cardiovascular death, 
stroke, and myocardial infarction occurred in 
379 patients (4.1%) vs 496 (5.4%) in the ASA 
group (P <0.001). The relative reduction of events 
was 24% (HR, 0.76). Interestingly, the high‑
est reduction of major events was related to 
stroke, which occurred in 142 patients (1.6%) 
in the ASA group, and in 83 (0.9%) in the ASA 
+ rivaroxaban group (HR, 0.58; P <0.001). In 
the combined treatment group, a higher inci‑
dence of major bleeding was observed, that is, 
in 288 patients (3.1%) vs 170 patients (1.9%), P 
<0.001. The relative increase in major bleeding 
incidence was 70% (HR, 1.7). The number of fa‑
tal bleeding episodes and intracranial bleeding 
episodes did not differ significantly between 
the groups. The number of deaths was lower in 
the rivaroxaban + ASA group than in the ASA 
group: 313 (3.4%) vs 378 (4.1%), respectively (HR, 
0.82; P = 0.01). Despite the significantly high‑
er number of bleeding complications, consid‑
ering the reduction of the composite endpoint, 
treatment with rivaroxaban, 2.5 mg twice dai‑
ly, combined with ASA, 100 mg once daily, pro‑
vided a clinical net benefit of 20% relative re‑
duction of cardiovascular events.
In the population of the COMPASS trial, 
90.5% to 90.8% of patients in each group had 
CAD, while PAD was present in 27.1% to 27.4% 
of the population. Peripheral artery disease was 
often accompanied by CAD. Aside from the out‑
comes for the entire COMPASS population, 
the trial outcomes were also assessed separate‑
ly in the stable CAD population and the periph‑
eral or carotid atherosclerosis group.34,35 The out‑
comes of these cohorts were consistent with 
the outcomes of the entire COMPASS trial. There 
are some aspects warranting closer attention 
in the assessed populations. The most common 
hemorrhagic complication was gastrointestinal 
bleeding. The trial also assessed the suitability 
of proton pump inhibitors for reducing the in‑
cidence of gastrointestinal bleeding, using pan‑
toprazole as the study drug. This part of the tri‑
al has not yet been published but may be useful 
for interpreting the outcomes.
Interestingly, a significant reduction of deaths 
was observed in patients with CAD treated with 
rivaroxaban and ASA, as compared to monother‑
apy with ASA: 262 (3%) of 8313 vs 339 (4%) of 
8261, respectively (HR, 0.77; P = 0.0012), which 
was not observed in the PAD group. The differ‑
ence may be caused by the size of the population. 
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clinical benefits arising from the newly discov‑
ered action of NOACs have thus far been con‑
firmed for one drug from this group, rivaroxa‑
ban. In the randomized, multicenter COMPASS 
trial, conducted on a study population of over 
27 000 patients with stable CAD and/or PAD, it 
was shown that in the group treated with riva‑
roxaban combined with ASA, the primary out‑
come (composed of cardiovascular death, stroke, 
and myocardial infarction) occurred signifi‑
cantly less frequently than in the group treated 
only with ASA.1 The relative reduction of events 
was 24%, with the incidence of stroke reduced 
the most. Also, the number of deaths was sig‑
nificantly lower in the rivaroxaban + ASA group 
than in the ASA alone group. Despite the sig‑
nificantly higher number of bleeding complica‑
tions, considering the reduction of the compos‑
ite endpoint, treatment with rivaroxaban, 2.5 mg 
twice daily, combined with ASA, 100 mg, provid‑
ed a clinical net benefit of 20% relative reduc‑
tion of cardiovascular events. In the subgroup 
of patients with PAD, a significant reduction of 
the incidence of major adverse limb events was 
shown, including amputations.
It appears that the outcomes of the COM‑
PASS trial might be a new era in the treatment 
of atherosclerosis. Given the huge population of 
patients with CAD (approx. 3 million individu‑
als) and/or PAD in Europe and in Poland, and 
the fact that cardiovascular diseases remain 
the main cause of death in Poland (51% in wom‑
en and 41% in men, including patients in their 
productive age, ie, 18–65 years), any new ther‑
apy reducing the number of deaths and disabil‑
ities caused by arterial diseases is very impor‑
tant.38 All the more so, the excess of the mor‑
tality rate in Poland is very high: 38% of men 
and 17% of women die before reaching the age 
of 65, which is the highest rate in the Euro‑
pean Union.39,4 0 The majority of those deaths 
are caused by cardiovascular diseases, most‑
ly atherosclerosis. Therefore, the outcomes of 
the COMPASS trial can be expected to be includ‑
ed in the next edition of the ESC guidelines on 
the diagnosis and management of stable CAD 
and PAD. FIGURE 3 is the key illustration of the ex‑
perts’ opinion on the use of NOACs in patients 
with atherosclerosis of coronary and periph‑
eral arteries in the context of other trials on 
antiplatelet and anticoagulation therapies. It 
should also be pointed out that the figure does 
not address stroke prevention in patients with 
AF. These trials are discussed in the section “Out‑
comes of randomized trials comparing vitamin 
K antagonists and non–vitamin K antagonist 
oral anticoagulants in patients with atrial fi‑
brillation undergoing percutaneous coronary 
intervention.”
Finally, the outcomes of the COMMANDER 
HF trial (A Study to Assess the Effectiveness and 
Safety of Rivaroxaban in Reducing the Risk of 
with rivaroxaban, 2.5 mg twice daily, and ASA, 
100 mg, provides long‑term clinical benefits both 
in stable CAD and in symptomatic PAD. Riva‑
roxaban, 2.5 mg twice daily, coadministered 
with ASA was registered for the prevention of 
atherothrombotic events in adult patients with 
CAD or symptomatic PAD at high risk of isch‑
emic events.
Summary Oral anticoagulants are widely used 
for prevention of systemic thromboembolism, 
including the aim to reduce the risk of stroke in 
patients with AF and prosthetic heart valves. On 
the other hand, there is an increasing popula‑
tion of patients who require not only OACs but 
also DAPT. A typical example is a patient with AF 
and stable CAD or ACS, treated by PCI. The deci‑
sion on the duration of triple therapy with OACs 
and DAPT is not an easy one and must be made 
based on the individual risk assessment of fur‑
ther thrombotic events, such as death, myocar‑
dial infraction, or ischemic stroke, and balanc‑
ing the effect of treatment on the risk of major 
bleeding complications, such as hemorrhagic 
stroke and gastrointestinal bleeding, to deter‑
mine the safety of the selected therapy. In recent 
years, with the introduction of NOACs, triple or 
dual therapy (NOAC + P2Y12 inhibitor) has be‑
come safer and its efficacy is at least compara‑
ble to older drugs, namely, VKAs. This has been 
confirmed for 2 NOACs available on the Polish 
market: dabigatran (thrombin inhibitor) and 
rivaroxaban (coagulation factor Xa inhibitor). 
The outcomes of randomized trials with apix‑
aban and edoxaban (both factor Xa inhibitors) 
will be published soon.
Regardless of the indications for the use of 
NOACs arising from the risk of stroke, and dif‑
ferent concepts for treatment of patients who re‑
quire simultaneous administration of antiplate‑
let agents due to PCI, rivaroxaban in the reduced 
(“vascular”) dose has been proved to efficient‑
ly reduce the risk of further thrombotic events 
when added to DAPT in patients who have suf‑
fered an ACS. However, the ECS guidelines rec‑
ommend caution, because such therapy increases 
the incidence of bleeding complications. The im‑
portance of an individual risks and benefits as‑
sessment cannot be overstated, hence the class 
of recommendation IIb (“may be considered”). 
The fact that it was no longer necessary to peri‑
odically assay INR and adjust the dose accord‑
ingly, as with the older generation of anticoag‑
ulants, acenocoumarol and warfarin, has also 
bolstered the popularity of NOACs.
The most interesting development, howev‑
er, was the one nobody had anticipated, name‑
ly, the potential impact of the pleiotropic mech‑
anism of action of NOACs through PAR1 and 
PAR2, present on the platelets and many oth‑
er cells, and changing the course of atheroscle‑
rosis of coronary and peripheral arteries. These 
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Death, Myocardial Infarction or Stroke in Par‑
ticipants With Heart Failure and Coronary Ar‑
tery Disease Following an Episode of Decom‑
pensated Heart Failure), announced and simul‑
taneously published at the 2018 ESC Congress, 
should be briefly discussed.41 A total of 5022 pa‑
tients with heart failure and increased levels of 
natriuretic peptides and left ventricular ejection 
fraction of 40% or less, CAD, and sinus rhythm, 
were treated with rivaroxaban, 2.5 mg twice dai‑
ly, or placebo. Patients took drugs prescribed for 
heart failure (99.5%) and ASA (93.1%) or DAPT 
(34.8%). The incidence of the composite end‑
point (all‑cause death, stroke, and myocardial 
infarction) was similar in both groups, with sim‑
ilar levels of safety of both therapies. These out‑
comes show that both the basic mechanism of 
action of rivaroxaban (impact on the coagulation 
system) and the potential impact of pleiotropic 
mechanisms, that is, the drug’s action through 
the aforementioned PAR1 and PAR2, are prob‑
ably not the source of cardiovascular events in 
patients with heart failure.
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